Next Article in Journal
Cell-Penetrating Fragments of the Cdk5 Regulatory Subunit Are Protective in Models of Neurodegeneration
Next Article in Special Issue
Prospects for the Use of ATR Inhibitors to Treat Cancer
Previous Article in Journal
New Trends in Cancer Therapy: Targeting Ion Channels and Transporters
Previous Article in Special Issue
Role of Glycogen Synthase Kinase-3β in APP Hyperphosphorylation Induced by NMDA Stimulation in Cortical Neurons
Article Menu

Export Article

Open AccessReview

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma

Department of Human Anatomy and Histology, University of Bari Medical School, Piazza G. Cesare, 11, Policlinico 70124, Bari, Italy
Pharmaceuticals 2010, 3(4), 1225-1231;
Received: 9 March 2010 / Revised: 21 April 2010 / Accepted: 22 April 2010 / Published: 22 April 2010
(This article belongs to the Special Issue Protein Kinase Inhibitors)
PDF [169 KB, uploaded 22 April 2010]


Tyrosine kinase inhibitors are a new class of anticancer drugs, that are capable of directly interacting with the catalytic site of the target enzyme and thereby inhibiting catalysis. Therapeutically useful tyrosine kinase inhibitors are not specific for a single tyrosine kinase, but rather they are selective against a limited number of tyrosine kinases. The success of imatinib-mesylate (Gleevec®) for the treatment of patients with chronic myeloid leukemia has opened a intensive search for new small molecular compounds able to target other protein tyrosine kinases involved in the malignant transformation. This review article is focused on the use of tyrosine kinase inhibitors as antiangiogenic molecules in the treatment of multiple myeloma. View Full-Text
Keywords: angiogenesis; antiangiogenesis; multiple myeloma; tyrosine kinase inhibitors angiogenesis; antiangiogenesis; multiple myeloma; tyrosine kinase inhibitors
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Ribatti, D. Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma. Pharmaceuticals 2010, 3, 1225-1231.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top